Topiramate in migraine prophylaxis;Topiramato en la profilaxis de la migraña

Revista de Neurologia

Volumn 43, Issue 5, 2006, Pages 257-258

  Láinez Andrés, José M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPRANOLOL; TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE; NEUROPROTECTIVE AGENT;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONCENTRATION LOSS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EPILEPSY; EVIDENCE BASED MEDICINE; HUMAN; LANGUAGE DISABILITY; MAINTENANCE THERAPY; MEMORY DISORDER; MIGRAINE; PARESTHESIA; FEMALE; MALE; NOTE;

ANTICONVULSANTS; FEMALE; FRUCTOSE; HUMANS; MALE; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS;

EID: 35348892754     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4305.2006412     Document Type: Editorial

References (16)

1. Russel MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex ratio of the subtypes of migraine. Int J Epidemiol 1995; 24: 612-8.
2. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53: 65-72.
3. Láinez JM. Epidemiología e impacto socioeconómico de la migraña. In Pascual J, ed. Migraña. Barcelona: Masson; 2001. p. 1-17.
4. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429-40.
5. Freitag F, Collins S, Carlson H, Goldstein J, Saper J, Silberstein S, et al, Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-9.
6. Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-8.
7. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 40 (Suppl 1): S61-5.
8. Edwards KR, Glantz MJ, Norton JA, Cross N. Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients [abstract]. Cephalalgia 2000; 20: 316.
9. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41: 968-75.
10. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
11. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al, MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 25: 965-73.
12. Diener HC, Tfelt-Hansen P, Dahlof C, Láinez MJ, Sandrini G, Wang SJ, et al, MIGR-003 Study Group. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943-50.
13. Pascual J, Sánchez del Río M, Mateos V, Láinez JM, Hernández-Gallego J, Leira R, et al. Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurología 2003; 18: 364-7.
14. Gracia-Naya M, Latorre-Jiménez AM. Topiramato o flunaricina en el tratamiento preventivo de la migraña. Estudio comparativo de dos series de casos. Rev Neurol 2005; 41: 705-8.
15. Medrano V, Sempere AP, Morera-Guitart J, Fernández-Izquierdo S, Espinosa-Martínez J. El tratamiento preventivo con topiramato mejora la calidad de vida de los pacientes con migraña. Rev Neurol 2006; 43: 259-63.
16. Láinez MJ, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache 2003; 43: 784-9.